Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Advances Market Access for Botanical Drugs Botreso and PCP

Jyong Biotech Ltd. announced advancements in market access strategies for its innovative plant-based drugs, Botreso and PCP, following an analysis of their clinical efficacy and competitive advantages. Botreso has completed four Phase III clinical trials in the U.S. and Taiwan, while PCP successfully completed its Phase II trial. Clinical data indicate significant differentiated advantages over synthetic chemical drugs, particularly regarding safety for long-term use, prostate cancer prevention, and comprehensive "Treatment + Prevention + Metabolic Management" benefits. The company highlights the excellent safety profile of both drugs, with no drug-related serious adverse events observed over one-year (Botreso) and two-year (PCP) medication periods, contrasting with side effects of current synthetic BPH treatments. PCP's Phase II trial, a large-scale study in Taiwan involving 702 subjects, showed a trend in reducing overall and high-grade prostate cancer incidence. Jyong Biotech believes its integrated approach, offering LUTS improvement, cancer prevention, and metabolic protection, is unique and appealing to men over 40.

• Jyong Biotech's botanical drugs, Botreso (Phase III) and PCP (Phase II), demonstrated excellent safety and tolerability over one and two-year medication periods, respectively, with no drug-related serious adverse events. This contrasts sharply with synthetic BPH drugs, which are associated with side effects like orthostatic hypotension, erectile dysfunction, decreased libido, and regulatory warnings from the US FDA regarding high-grade prostate cancer, depression, and suicidal ideation.
• The PCP Phase II trial, a significant two-year study involving 702 subjects across 20 major hospitals in Taiwan, showed a promising trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer (Gleason Score ≥ 7). This finding directly addresses a critical safety concern associated with some synthetic BPH treatments, which, despite reducing overall incidence, may paradoxically increase the proportion of high-grade cancers.
• Jyong Biotech's drugs offer a unique, integrated approach combining effective improvement of Lower Urinary Tract Symptoms (LUTS) with prostate cancer prevention potential. Furthermore, they provide significant metabolic and cardiovascular protection by reducing triglycerides (P=0.05), significantly lowering total cholesterol and LDL (P<0.05), and increasing HDL (P<0.05), all while maintaining stable blood sugar and without negatively affecting blood pressure, liver, or kidney function.
• The company emphasizes its robust technological platform for botanical new drug development, which creates high barriers to entry and mitigates generic competition, extending market exclusivity. This unique profile, including high tolerability, excellent safety, and multiple clinical benefits, supports premium pricing, offers strong licensing potential for international partnerships, and expands the product scope into preventative medicine and health management, targeting a global BPH market projected to reach $9.8 billion by 2026.

Botreso and PCP: Differentiating in the BPH Landscape

Recent clinical evidence demonstrates that minimally invasive surgical therapies (MISTs) are emerging as compelling alternatives to traditional surgical interventions for BPH treatment. Five representative MISTs—water vapor thermal therapy (WVTT), prostatic urethral lift (PUL), prostatic artery embolization (PAE), temporary implantable nitinol device (iTIND), and Aquablation—show distinct efficacy profiles compared to standard treatments. Long-term data reveal WVTT provides 48% IPSS reduction at 5 years, while PUL achieves 35% IPSS improvement over the same timeframe. Notably, Aquablation demonstrates superior safety regarding sexual function, with lower retrograde ejaculation rates than TURP, and both WVTT and PUL report no new sexual dysfunction. Most MISTs offer the advantage of outpatient procedures under local anesthesia, contrasting with the inpatient requirements of traditional surgical approaches.

Comparative studies with established surgical standards reveal nuanced therapeutic positioning for investigational approaches. A prospective randomized trial comparing PAE with TURP in 60 patients with moderate-to-severe LUTS refractory to medical therapy aimed to establish non-inferiority, with PAE described as an effective and safe alternative procedure. For larger prostates (80-150 cc), Aquablation showed robust efficacy with mean IPSS improvement from 23.2 to 5.8 at 2 years and maximum urinary flow increase from 8.7 to 18.2 cc/sec, demonstrating comparable outcomes to traditional approaches while maintaining low retreatment rates. Long-term follow-up data from a 10-year comparison of TURP, contact laser prostatectomy (CLP), and electrovaporization (EVAP) showed similar durable improvements in symptom scores across all modalities, though only TURP maintained statistically significant improvements in maximum flow rate.

The therapeutic landscape reveals distinct advantages for investigational approaches in specific patient populations and prostate characteristics. For prostates exceeding 80 cm³, PAE achieved greater than 44% volume reduction, while Aquablation demonstrates the strongest evidence base for larger prostates. WVTT and PUL receive guideline recommendations for medium-sized glands, and PAE shows particular suitability for older or high-risk patients who may not tolerate traditional surgery. Beyond surgical innovations, investigational medical approaches include vitamin D supplementation, which demonstrated statistically significant reductions in prostate volume and PSA levels compared to placebo in a randomized trial of 108 participants, alongside modified combination therapy protocols showing improved cost-effectiveness and superior maximum urinary flow rates compared to standard medical regimens.

Plant-Based Therapies: A Holistic Future for Prostate Care

Jyong Biotech's recent announcement regarding its plant-based drugs, Botreso and PCP, signals a potentially transformative shift in the management of benign prostatic hyperplasia (BPH) and broader men's prostate health. With Botreso having completed Phase III trials and PCP a large-scale Phase II study, the company is positioning these therapies as offering significant differentiated advantages over conventional synthetic drugs. The emphasis on an excellent safety profile for long-term use, coupled with a comprehensive "Treatment + Prevention + Metabolic Management" benefit, addresses a critical unmet need for men over 40 seeking sustained relief from lower urinary tract symptoms (LUTS) without the typical side effects associated with current synthetic BPH treatments.

The prospect of a plant-based drug like PCP demonstrating a trend in reducing overall and high-grade prostate cancer incidence is particularly compelling. Existing literature supports the therapeutic potential of herbal medicines in BPH, with studies showing plant extracts can inhibit prostate tissue growth and modulate key pathways like androgen receptor and 5α-reductase. If Jyong Biotech can definitively establish these preventative benefits in further trials, it could redefine the standard of care, moving beyond mere symptom management to a more holistic approach that includes disease prevention. This integrated strategy could carve out a unique market niche, appealing to a demographic increasingly interested in natural, long-term health solutions.

However, the path forward is not without its complexities. The pharmaceutical landscape for herbal medicinal extracts is fraught with challenges, including variable bioavailability, intricate pharmacokinetics, and the critical need for stringent standardization and quality control. While Jyong Biotech's progress through clinical phases is encouraging, ensuring batch-to-batch consistency and navigating regulatory scrutiny for these complex botanical formulations will be paramount. Furthermore, while the "trend" in prostate cancer reduction is promising, converting this into a robust, regulatorily accepted prevention claim will require substantial, long-term data from well-designed Phase III studies. The established BPH market, currently dominated by synthetic alpha-blockers and 5-alpha-reductase inhibitors, also presents a competitive environment. Overcoming potential physician skepticism towards plant-based therapies, especially given historical concerns about methodological quality in some herbal medicine research, will be crucial for widespread adoption. Jyong Biotech's success will hinge on its ability to clearly articulate the scientific rigor behind its products and demonstrate undeniable clinical superiority and safety in real-world settings.